Immune Cell Therapy Development Services
Immune cell therapy, also known as adoptive cell therapy, is a revolutionary cancer treatment that uses the cells of our immune system to eliminate cancer. Alfa Cytology's integrated multidisciplinary team focuses on providing preclinical research-based services and a wide range of solutions for every stage of immune cell therapy development, to help clients develop innovative therapies that break through the limitations of traditional therapeutics.
Introduction to Immune Cell Therapy
Immune cell therapy utilizes multiple types of immune cells to precisely target and eradicate cancer cells in the following process.
- Recognition and Targeting. Immune cells recognize specific molecules or antigens present on the surface of cancer cells. For example, CAR-T cells are designed to target tumor-specific antigens, while NK cells have the inherent ability to recognize and kill cancer cells.
- Activation and Proliferation. Immune cells are injected into the patient and activated upon encountering cancer cells, subsequently triggering a series of immune responses that lead to the proliferation and expansion of the immune cells, thereby enhancing the anti-cancer immune response.
- Effector Functions. Immune cells execute effector functions to eliminate cancer cells. These involve the release of cytotoxic molecules, induction of apoptosis in cancer cells, and recruitment of other immune cells to the tumor site to enhance the immune response.
Fig.1 Common forms of immunotherapies. (Li, C. M. Y., et al., 2023)
Advantages of Immune Cell Therapy
Immune cell therapy demonstrates multiple advantages over traditional cancer treatments.
- Precision and Specificity. Immune cell therapies can be engineered to target specific molecules present in cancer cells, minimizing damage to healthy tissues and reducing side effects associated with traditional therapies.
- Long-lasting Immune Memory. Successful immune cell therapies can induce long-lasting immune memory, providing ongoing surveillance against cancer recurrence even after treatment completion.
- Treatment of Resistant Cancers. Immune cell therapies offer a promising approach for treating cancers that are resistant to conventional treatments like chemotherapy and radiation therapy, providing new hope for patients with advanced or refractory disease.
Our Services
Alfa Cytology understands the complexity of immune cell therapy development. For different program needs and different types of immune cell therapies, we combine multiple platform technologies to support you throughout the immune cell therapy workflow.
TIL Therapy Development Services for Cancer
Tumor-infiltrating lymphocyte (TIL) therapy, involves isolating and expanding T cells from a tumor tissue and reintroducing them to target and destroy cancer cells. Alfa Cytology has integrated breakthrough technologies such as next-generation sequencing and adoptive cell transfer techniques, to provide preclinical stage services ranging from the characterization of key TIL attributes, to accurate efficacy evaluations and toxicity testing aimed at improving the therapeutic efficacy of TIL therapy.
CAR T-cell Therapy Development Services for Cancer
Chimeric antigen receptor T-cell (CAR-T) therapy, engineers T cells to express synthetic receptors targeting specific tumor antigens. Alfa Cytology's services include the development of novel CAR designs using gene editing and bioinformatics approaches to enhance target specificity and reduce off-target effects in order to optimize the therapeutic efficacy of CAR T-cell therapies for many different types of cancer.
TCR Therapy Development Services for Cancer
T-cell receptor (TCR) therapy, involves genetically modifying T cells to express tumor-specific T-cell receptors for enhanced anti-tumor activity. Alfa Cytology leads TCR therapy development through innovative antigen discovery platforms and rational design of TCR constructs. Our integrated approach includes antigen identification, TCR optimization, and preclinical validation, ensuring the robustness and efficacy of TCR-based cancer immunotherapy.
NK Cell Therapy Development Services for Cancer
NK cell therapy harnesses the innate cytotoxicity of natural killer cells to eliminate cancer cells without prior sensitization. Our cutting-edge technologies enable the expansion and activation of NK cells ex vivo, enhancing their anti-tumor potency. Alfa Cytology's unique services in NK cell therapy encompass optimization of culture conditions, genetic engineering for improved functionality, and combination strategies to overcome tumor immune evasion mechanisms.
CIK Cell Therapy Development Services for Cancer
Cytokine-induced killer (CIK) cell therapy, involves ex vivo expansion of peripheral blood mononuclear cells with cytokine stimulation to enhance their anti-tumor activity. Alfa Cytology leverages advanced cell culture techniques and cytokine cocktails to generate highly potent CIK cell populations. Our tailored approaches include co-culture with antigen-presenting cells and cytokine priming to enhance CIK cell persistence and tumor targeting capabilities.
Dendritic Cell Therapy Development Services for Cancer
Dendritic cell therapy utilizes dendritic cells as antigen-presenting cells to stimulate T-cell responses against cancer antigens. Through state-of-the-art dendritic cell isolation and maturation protocols, Alfa Cytology ensures the generation of potent dendritic cell vaccines. Our expertise in dendritic cell therapy extends to antigen loading strategies, adjuvant selection, and combination with other immunotherapeutic modalities to maximize anti-tumor immunity.
With deep expertise in tumor immunology and extensive research experience, Alfa Cytology offers simplified, streamlined, customizable, and scalable solutions for the development of immune cell therapy. Our services involve immune cell preparation and optimization, phenotypic testing, cell model construction, in vitro analysis, and in vivo efficacy evaluation. Explore the services you are interested in using the search box above, or contact us directly to learn how we can help you accelerate the development and translation of innovative immunotherapies.
Reference
- Li, C. M. Y., et al.; (2023). Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges. Cancer Treatment Reviews, 102665.
For research use only.
Related Services
